throbber
J. Am. Chern. Soc. 1991, 113, 7433-7434
`
`7433
`
`most reasonably attributed to a rotational isotope effect, 11 is
`consistent with concert. For the isotope effect to be consistent
`with the stereospecific biradical pathway, closure to the five(cid:173)
`membered ring must be rate-determining. However, it is hard
`to reconcile the demand of slow closure to a five-membered ring
`relative to closure to a three-membered ring with the demand of
`rapid closure to a five-membered ring relative to bond rotation
`in the diradical. Thus, the 1 ,3-shift would appear to be concerted.
`
`Acknowledgment. We thank the National Science Foundation
`for financial support, Prof. Christopher Samuel (U. Warwick),
`who provided the initial NMR data and spectral analysis of the
`product epoxide to warrant pursuit of this work, and Prof. Kevin
`Gilbert for his continued interest in this problem.
`
`Supplementary Material Available: Experimental details for
`the synthesis of 1 and NMR spectra of the methylene protons of
`the undeuterated epoxide, the deuterate<! epoxide from the three
`different reaction times, and simulations of mixtures (9 pages).
`Ordering information is given on any current masthead page.
`
`(II) Dai, S. H.; Dolbier, J. J. Am. Chern. Soc. 1970,92, 1774; 1971,94,
`3946. Crawford, R. J.; Chang, M. H. Tetrahedron 1982,38, 837. Gajewski,
`J. J.; Benner, C. W.; Stahly, B. N.; Hall, R. F.; Sato, R.I. Tetrahedron 1982,
`38, 853.
`
`Atomic Structure of the Rapamycin Human
`Immunophilin FKBP-12 Complex
`
`Gregory D. Van Duyne,t Robert F. Standaert,l
`Stuart L. Schreiber, •.1 and Jon Clardy•·t
`Department of Chemistry, Cornell University
`Ithaca, New York 14853
`Department of Chemistry, Harvard University
`Cambridge, Massachusetts 02138
`Received June 3, 1991
`
`Complexes of immunophilins with immunosuppressive drugs
`interfere with a variety of signal transduction pathways in the
`cytoplasm of the cel1. 1- 3 Rapamycin4 (1) is a high affinity ligand
`(Kd = 0.2 nM) 2 to the immunophilin FKBP-12s-7 and appears
`to be a general and potent antiproliferative agent. 1 The pleiotropic
`actions of rapamycin on growth factor receptor signaling pathways
`have elevated this compound to a high status as a probe of sig(cid:173)
`naling mechanisms. Although the precise details have yet to be
`elucidated, the complex of human FKBP-12 and rapamycin has
`been shown by genetic methods to function as the inhibitory agent. 8
`Herein we report the three-dimensional structure of the complex
`of human FKBP-12 and rapamycin, determined to 1.7-A resolution
`
`'Cornell University.
`I Harvard University.
`(I) Schreiber, S. L. Science 1991, 251, 283.
`(2) Bierer, B. E.; Matila, P. S.; Standaert, R. F.; Herzenberg, L. A.;
`Burakoff, S. J.; Crabtree, G.; Schreiber, S. L. Proc. Nat/. Acad. Sci. U.S.A.
`1990, 87, 9231-9235.
`(3) Bierer, B. E.; Somers, P. K.; Wandless, T. J.; Burakoff, S. J.; Schreiber,
`S. L. Science 1990, 250, 556-559.
`(4) Findlay, J. A.; Radics, L. Can. J. Chern. 1980, 58, 519.
`(5) The family of proteins that bind to FK506 and rapamycin have been
`collectively named FKBP's (FK506 binding proteins), with a suffix designating
`the approximate molecular weight. Human FKBP-12, the most abundant
`FKBP found in the cytoplasm, is a 12 kD protein of I 07 amino acids that binds
`FK506 and rapamycin and catalyzes the cis-trans isomerization of pepti(cid:173)
`dyl-prolyl amide bonds in peptide substrates.
`(6) Harding, M. W.; Galat, A.; Uehling, D. E.; Schreiber, S. L. Nature
`1989, 341, 758.
`(7) Siekierka, J. J.; Hung, S. H. Y.; Poe, M.; Lin, C. S.; Sigal, N. H.
`Nature 1989, 341, 155.
`(8) Koltin, Y.; Faucette, L.; Bergsma, D. J.; Levy, M.A.; Cafferkey, R.;
`Koser, P. L.; Johnson, R. K.; Livi, G. P. Mol. Cell. Bioi. 1991, II, 1718.
`
`Figure 1. (a, top) A stereoview of the a-carbon tracing of FKBP-12 and
`rapamycin. TheN- and C-terminal a-carbons are labeled. (b, bottom)
`A stereodrawing of the binding pocket showing all of the bound rapa(cid:173)
`mycin molecule and selected FKBP-12 residues.
`
`by X-ray crystallographic techniques.9 This structure provides
`a framework to interpret the effects of structural perturbation of
`either rapamycin or human FKBP-12 on signal transduction
`pathways.
`
`OMe Me
`
`2- FKSOS
`1 • Rapamycin
`As shown in Figure 1, the protein component of the FKBP-
`12/rapamycin complex forms a five-stranded antiparallel ~-sheet
`
`(9) Crystals of the FKBP-12/rapamycin complex were grown from solu(cid:173)
`tions containing 10 mg/mL of protein complex, 300 mM ammonium sulfate,
`and 100 mM phosphate at pH 6.0 using the hanging droP. method at room
`temperature. The space group is n 12121 with a= 45.42 A, b = 49.16 A, c
`= 54.74 A, and one molecule in the asymmetric unit. Data were measured
`using a San Diego Multi wire Systems Mark II detector and a rotating anode
`source to 1.7-A resolution. A total of81484 reflections were measured (12991
`unique, 93% complete, R,)'lll • 0.056, 10633 with F ~ 3<T) from two crystals.
`The structure was solve<l using the molecular replacement method with a
`search model composed of the protein comronent of the FKBP-12/FK506
`complex and the MERLOT program system. 0 The structure was refined with
`X-PLOR11 using least-squares minimization by conjugate gradients where the
`stereochemical restraints used in ligand refinement were restricted to terms
`for bond lengths, bond angles, and improper dihedral angles (for planar sp2
`carbons and chiral centers). The conformation of bound rapamycin was
`determined unambiguously from well-defined electron density in 2F0-F0 maps.
`The R factor for the current model, including FKBP-12, rapamycin, and 85
`water molecules, is 0.165. All main chain atoms, all buried side-chain atoms,
`and all ligand atoms are well-defined in the final 2F0 - F0 electron density
`map. The root-mean-square deviations of bond lengths and bond angles from
`their ideal values are 0.01 A and 2.8°, respectively.
`(10) Fitzgerald, P. M. D. J. Appl. Crystallogr. 1988, 21, 273.
`(II) Br!lnger, A. T. X·PLOR Manual, Version 2.1; Yale University, New
`Haven, 1990.
`
`ooo2-7863/91 11513-7433$02.50/0
`
`© 1991 American Chemical Society
`
`

`
`7434
`
`J. Am. Chem. Soc. 1991, 113, 7434-7435
`
`wrapping with a right-handed twist around a short a-helix-the
`same folding topology found in the complex of FKBP-12 with
`FK50612 and in uncomplexed FKBP-12. 13•14 The root-mean(cid:173)
`square (rms) deviations of a-carbons, backbone atoms, and all
`protein atoms between FKBP-12 complexed with rapamycin and
`FKBP-12 complexed with FK506 are 0.67, 0.67, and 1.51 A,
`respectively. Only one region, involving residues 31-34 in the loop
`between strands 4 and 5 of the ~-sheet structure, adopts a different
`main chain conformation. These residues are not involved in
`protein-ligand interactions, but may be important recognition
`features of the complex.
`Rapamycin binds in a cavity between the ~-sheet and a-helix
`with the pipecolinyl ring deeply buried in the protein (Figure Ia).
`The protein-ligand interface involves atoms from the pyranose
`ring through the C28 hydroxyl, with the remainder, including the
`C17-C22 triene, exposed. The C1 ester, the pipecolinyl ring, the
`C8 and C9 carbonyls, and the pyranose ring adopt a conformation
`that is superimposable with the same groups in the FKBP-12/
`FK506 complex. 12 Three hydrogen bonds between this region and
`FKBP-12 (Ile-56 NH to C I carbonyl, Tyr-82 hydroxyl to C8
`carbonyl, and Asp-37 carboxylate to CIO hydroxyl) and a C9
`carbonyl binding pocket involving C-H .. ·O interactions with E·
`hydrogens from Tyr-26, Phe-36, and Phe-99 are also identical with
`those found in the complex with FK506, thus confirming the
`identical binding roles of the common structural elements15 in the
`two immunosuppressant ligands.
`Two additional hydrogen bonds are involved in rapamycin
`binding to FKBP-12 (Figure I b). The first is from Glu-54 main
`chain carbonyl to C28 hydroxyl, which along with the lie-56 NH
`to C 1 carbonyl-hydrogen bond may mimic the interaction of the
`dipeptide portion of a natural substrate with FKBP-12. It has
`been noted that the pyranose-pipecolinyl region also mimics a
`dipeptide, 16 making rapamycin, like FK506, a possible example
`of an extended peptide mimic. This hydrogen bond is analogous
`to the one from Glu-54 main chain carbonyl to C24 hydroxyl found
`in the FKBP-12/FK506 complex. 12 The second hydrogen bond
`is from Gln-53 main chain carbonyl to the C40 hydroxyl. In the
`rapamycin complex the cyclohexyl group (C35-C42) is bound
`to the protein through this hydrogen bond, while the FK506
`complex has no such cyclohexyl-protein interaction. FK506's (2)
`C27-c28 double bond restricts the orientations of the cyclohexane
`while in rapamycin (1) the cyclohexyl ring can swing about the
`C35-C36 bond to form a Gin-53 carbonyl to C40 hydroxyl hy(cid:173)
`drogen bond.
`The conformation of bound rapamycin is virtually identical with
`that seen in the free, crystalline state,4 with an rms difference of
`0.49 A. Unlike FK506, which undergoes a cis to trans isomer(cid:173)
`ization of the amide bond accompanied by a dramatic change in
`overall conformation on binding to FKBP-12, 12 rapamycin pos(cid:173)
`sesses a high degree of structural preorganization for binding. This
`preorganization, along with the anchoring of the cyclohexyl group,
`may explain the twofold higher affinity (Kd = 0.2 nM) of rapa(cid:173)
`mycin for FKBP-12 compared to FK506 (Kd = 0.4 nM).2
`The view of the FKBP-12/rapamycin complex as the biological
`effector in immunosuppressive function requires a focus on the
`complex as a whole-in particular the exposed regions of bound
`rapamycin and the FKBP-12 loops flanking the binding site. The
`likely role of FKBP-12 and other FKBP's in the disruption of
`signal transduction in T-cells is to present rapamycin (or FK506)
`to as yet unknown biological acceptors, or partner proteins. The
`FKBP-12/rapamycin complex described may be best viewed in
`this context as the ligand, now known at atomic resolution, to a
`partner protein involved in cytoplasmic signal transduction.
`
`( 12) VanDuyne, G. D.; Standaert, R. F.; Karplus, P. A.; Schreiber, S. L.;
`Clardy, J. C. Science 1991, 252, 839.
`(13) Michnick, S. W.; Rosen, M. K.; Wandless, T. J.; Karplus, M.;
`Schreiber, S. L. Science 1991, 252, 836.
`(14) Moore, J. M.; Peattie, D. A.; Fitzgibbon, M. J.; Thomson, J. A.
`Nature 1991, 351, 248.
`(I 5) Wandless, T. J.; Michnick, S. W.; Rosen, M. K.; Karplus, M.;
`Schreiber, S. L. J. Am. Chern. Soc. 1991, 1/3, 2339.
`(16) Albers, M. W.; Walsh, C. T.; Schreiber, S. L. J. Org. Chern. 1990,
`55, 4984.
`
`Acknowledgment. We thank T. J. Stout and P. A. Karplus for
`technical assistance and Walt Cullen and Jack Oscarson of the
`National Products Discovery and Fermentation Department at
`Pfizer, Inc. for supplying the rapamycin used in this study.
`Support from the National Cancer Institute (CA-24487, J.C.)
`and the National Institute of General Medical Sciences (GM-
`38627, S.L.S.) is gratefully acknowledged. The area detector
`facility was supported by NSF Grant DIR-8820910. Coordinates
`of the bound rapamycin molecule are available from the authors.
`The complete refined coordinates of the FKBP-12/rapamycin
`complex will be deposited in the Brookhaven Protein Databank.
`
`Self-Assembling, Alkali-Metai-Complexing Nickel
`Salicylaldimine Complexes
`Otto F. Schall, Kerry Robinson,t Jerry L. Atwood,t and
`George W. Gokel *
`Departments of Chemistry, University of Miami
`Coral Gables, Florida 33124
`University of Alabama, University, Alabama 35487·0336
`Received May 23, 1991
`
`Nature often achieves biological function in large molecules
`that are shaped and ordered by various feeble forces such as
`hydrogen bonding, salt-bridge formation, 11'-Stacking, etc. We1
`and others2 have been interested in this phenomenon especially
`from the perspective of developing relatively small molecular hosts
`that can assemble, organize, and bind. This phenomenon has two
`manifestations that should be distinguished, however. On the one
`hand, there are those that self-assemble to bind with little
`structural change. 3 On the other, there are hosts such as car(cid:173)
`boxypeptidase A that undergo significant structural change
`("induced-fit system") when a guest is bound.4 A model in the
`former category was devised by Reinhoudt et al., who used a
`macrocyclic salen-polyether-U02 complexes to afford a binding
`site for urea. 5 We now report an unusual nickel salicylaldimine
`system that was thought6 to be in the former category but actually
`forms an unusual bimetallic molecular cage.
`3-Hydroxysalicylaldehyde was converted into a series of 3-
`alkoxy-N-methylsalicylaldimine derivatives as previously de(cid:173)
`scribed.6 The side arms in the 3-position included methyl (CH3,
`1), 2-methoxyethyl (CH2CH20CH 3, 2), and 2-(2-methoxyeth(cid:173)
`oxy)ethyl (CH2CH20CH2CH20CH 3, 3). It is known that such
`aldimine systems react with nickel to form square-planar nickei(II)
`complexes of the NiL2 variety. 7 These complexes may undergo
`tetrahedral-square planar equilibria if the system is sterically
`hindered. Some diamagnetic, square-planar complexes further
`associate by forming paramagnetic dimers.8 We isolated the
`complex 12Ni as previously reported.6 The combustion analysis
`and mass spectrum were compatible with the indicated stoi(cid:173)
`chiometry. Assessment of stoichiometry in such cases by vapor
`pressure osmometry (VPO) has been eschewed as the results do
`not always accord with those of cryoscopic studies (see supple(cid:173)
`mentary materia1).9 Our studies using VPO indicated that 12Ni
`
`1 University of Alabama.
`(I) (a) Kim, M.; Gokel, G. W. J. Chern. Soc., Chern. Commun. 1987,
`1686. (b) Medina, J. C.; Li, C.; Bott, S. G.; Atwood, J. L.; Gokel, G. W. J.
`Am. Chern. Soc. 1991, 1/3, 367. (c) Gokel, G. W.; Medina, J. C.; Li, S.
`Synlett, in press.
`.
`.
`(2) (a) Rebek, J., Jr. Top. Curr. Chern. 1988, 149, 189. (b) Shmka1, S.;
`Miyazaki, K.; Manabe, 0. J. Chern. Soc., Perkin Trans. 2 1987, 449.
`(3) Hamilton, A. Adv. Supramolecular Chern. 1990, 1, I.
`(4) (a) Hartsuck, J. A.; Lipscomb, W. N. Enzymes 1971, 3, I.
`(b)
`Quiocho, F. A.; Lipscomb, W. N. Adv. Protein Chern. 1971, 25, I. (c)
`Lipscomb, W. N. Proc. Nat/. Acad. Sci. U.S.A. 1980, 77, 3875.
`(5) Van Staveren, C. J.; van Erden, J.; van Veegel, C. J. M.; Harkema,
`S.; Reinhoudt, D. N.J. Am. Chern. Soc. 1988, 110, 4994-5008.
`(6) Schepartz, A.; McDevitt, J. J. Am. Chern. Soc. 1989, Ill, 5976.
`(7) (a) Holm, R. H.; Everett, G. W., Jr.; Chakravarty, A. Prog. lnorg.
`Chern. 1966, 7, 83. (b) Holm, R. H.; O'Connor, M. J. Prog. lnorg. Chern.
`1971, 14, 241.
`(8) Holm, R. H. J. Am. Chern. Soc. 1961, 83, 4683.
`(9) (a) Holm, R. H.; Swaminathan, K. lnorg. Chern. 1962, /, 599. (b)
`Holm, R. H.; Swaminathan, K. lnorg. Chern. 1963, 2, 181.
`
`0002-7863/91/1513-7434$02.50/0 © 1991 American Chemical Society

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket